Our data indicate that 20(S)-PPD treatment downregulates the Bcl-XL and MCL-1 expression, while the levels of Bax, Bak, Bcl-2 and Bfl-1 remaind unchanged in three tested AML cells (Figure 2). The gene discussed is BCL2; the disease is acute myeloid leukemia.